Three class action Lawsuits alleging SEC breaches have been filed on behalf of shareholders, just a week after the CEO of Athira Pharma was placed…
Posts published by “Daniel Scott”
Considered an asset in Health Courier, Daniel is revered for his degree in Biotechnology. Daniel is also renowned for his additional skills such as strategic planning, marketing skills, and organizational demeanor. Scott is highly revered for his exceptional dexterity in technical writing. Owing to his academic background in Biotechnology, Daniel has also actively participated in journalism workshops, besides undertaking a dedicated course in writing to further solidify his skill-set in objective journalism. One of the most talked-about roles of Daniel was his short stint in one of the leading news houses wherein he left an indelible mark in a new presentations. Gradually, Daniel diverted into editing, which he continued to do over the years in both print and electronic media.
The impact of the present COVID-19 Pandemic on the industry was examined and researched in a report issued by Market Research Store on the worldwide…
Vita Therapeutics: The Baltimore, Maryland-based Firm announced a $32 million Series A funding round oversubscribed. Cambrian Biopharma led the way, with Kiwoom Bio, SCM Life Sciences,…
Frank Bennett, Ph.D., Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals, Inc., has been named a co-recipient of the 23rd Jacob and Louise…
The approval of a Biogen Inc medicine to treat Alzheimer’s disease by US authorities on Monday could rekindle investor interest in biotech and pharmaceutical stocks,…
There has been a highly speculative environment surrounding Genetic Modified Organisms (GMO), creating fear among the population. A community of anti-GMO activists have frequently claimed…
The final Phase 3 results were released last November showing that the Messenger RNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective.…
At Genentech in 2007, there were five times as many males as women in officer positions, and female directors (the level above officers) were leaving…
Regeneron Pharmaceuticals Inc. shares inched 0.16% higher to $503.23 Tuesday. This proved to be an all-around mixed trading session for the stock market, with the…
The US Food and Drug Administration (FDA) will make its final decision on whether to approve aducanumab, Biogen’s Alzheimer’s disease drug, by next Tuesday. The…